Tag: prospectus

$4 million upfront with up to an additional $4 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

SINGAPORE, June 19, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. (“OMS” or the “Company”) (Nasdaq: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, today provided a business update outlining its recent accomplishments as the Company prepares for its inaugural earnings call following its successful Nasdaq listing in May 2025.

Paris, 19 June 2025

TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- (TSX: PIC.A; PIC.PR.A) Premium Income Corporation (the “Fund”) announces results of operations for the six months ended April 30, 2025. Decrease in net assets attributable to holders of Class A shares amounted to $5.7 million or $0.38 per Class A share. Net assets attributable to holders of Class A shares as at April 30, 2025 were $81.2 million or $5.12 per Class A share. Cash distributions of $0.64 per Preferred share and $0.48 per Class A share were paid during the period.

Ad Hoc Announcement Pursuant to Art. 53 LR

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Mount Logan Capital Inc. (Cboe Canada: MLC) (“Mount Logan,” “our,” “we,” or the “Company”) announced that at the annual meeting of shareholders held on June 18, 2025 (the “Meeting”), each of the six nominees listed in the management information circular dated May 13, 2025 (the “Circular”) were elected as directors of the Company. A total of 31,979,130 votes or 55.78% of Mount Logan’s issued and outstanding common shares were voted in connection with the Meeting. The detailed results of the vote for each of the six elected directors are set out below.

New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the closing of its initial public offering (the “Offering”) of 2,666,667 ordinary shares (the “Ordinary Shares”) at a public offering price of $7.5 per share for aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares commenced trading on Nasdaq Global Market on June 17, 2025, under the ticker symbol “MENS”. The Offering closed on June 18, 2025.